跳至主要内容
临床试验/NCT02861196
NCT02861196已完成不适用

Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2015年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
59
试验地点
1
主要终点
bladder preservation rate

研究概览

简要总结

This research aims to explore the therapeutic effect of neoadjuvant chemotherapy in muscular invasive bladder cancer of T2-4aN0M0, and the survival effect of combined-modality treatment model,then to clarify the probability of bladder preservation, corresponding cancer specific survival, and the quality of life.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • bladder urothelium carcinoma
  • life expectancy≥1 year
  • ECOG PS 0-1
  • have no previously received radiotherapy or chemotherapy
  • have no major organ dysfunction
  • have been provided informed written consent

排除标准

  • extensive carcinoma in situ or ureter invaded
  • distant metastasis at primary diagnosis or lymphatic metastasis according to clinical diagnosis
  • have severe major organ dysfunction
  • cannot finish treatments because of other severe diseases or life expectance≤6 months
  • exist other malignant tumors
  • have severe coagulation disorders
  • no other trails participated in 4 weeks

结局指标

主要结局

bladder preservation rate

时间窗: 3 years

bladder preservation rate

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jianzhong Shou

Clinical Professor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究点 (1)

Loading locations...

相似试验